Loading... (0%)
About liver disease

GENFIT: The NASH Education Program™ – Inaugural Press Conference, Paris – March 9, 2017

› Inaugural event for the launch of The NASH Education Program™ endowment fund, Hôtel de Sers (Paris) – March 9, 2017 from 9am to 1pm

› With the participation of the President of its Scientific Committee, Professor Sven Francque, Head of Department, Gastroenterology and Hepatology Antwerp University Hospital, Antwerp, Belgium, as well as Professor Bertrand Cariou, Director of the Thorax Institute (Institut du Thorax), Nantes University Hospital, France, also a member of the Scientific Committee

› Presentation of the mission, the objectives, the means, and the first initiatives of the fund engaged or planned for 2017

Lille (France), Cambridge (Massachusetts, United States), February 14, 2017 – GENFIT (Euronext: GNFT – ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that a press conference will be held for the launch of The NASH Education Program™, its endowment fund created at the end of 2016.

The press conference will be the opportunity to present the action plan for the disease awareness activities aimed at disseminating scientific and medical knowledge about NASH, to the medical community, patients, and the general public.

The event will be hosted by The NASH Education Program™’s Scientific Committee President Pr. Sven Francque, MD, PhD, Head of Department, Gastroenterology and Hepatology Antwerp University Hospital, Antwerp, Belgium, and by Pr. Bertrand Cariou, Director of the Thorax Institute (Institut du Thorax), Nantes University Hospital, France, also a member of the Scientific Committee.

While most advanced drug-candidates are currently being evaluated in a final clinical trial phase before commercialization in NASH, including GENFIT’s lead compound elafibranor, GENFIT is preparing for the future.

The NASH Education Program™’s ambition is indeed to contribute to the global effort aimed at developing disease awareness in relation to public health challenges brought on by the development of NASH, and at increasing knowledge around the disease without waiting for the first diagnostic and therapeutic solutions to be available on the market.

The NASH Education Program™ will design, fund, and support collaborative approaches involving partners from different backgrounds such as academic, corporate, or regulatory, and with the potential to create valuable synergies in the NASH space, for the best patient care. Volunteers will also have the opportunity to contribute to various initiatives.

Jean-François Mouney, Chairman & CEO of GENFIT, and President of The NASH Education Program™ commented: “This event symbolizes the commitment of brilliant health specialists at the service of NASH patients, as shown by Professors Francque’s and Cariou’s involvement in the Scientific Committee. It will give us the opportunity to explain how The NASH Education Program™ is intending to provide concrete and pragmatic answers to the large unmet needs that exist today when it comes to scientific and medical knowledge around NASH and its related challenges. It will also be the occasion to provide a global picture about the first initiatives engaged or planned by The NASH Education Program™ in this direction as early as 2017. As a leader in the development of diagnostic and therapeutic solutions for NASH, one of GENFIT’s responsibilities is also to drive actions related to healthcare education. The level of interest demonstrated since we first announced this initiative reinforces our belief that collaborative approaches are a good way to move forward in the field.

About The NASH Education Program™:

The NASH Education Program™ is an endowment fund created end of 2016, with the objective to develop disease awareness initiatives around NASH, and as such address unmet information needs across a large set of stakeholders in the disease. Its investments should allow the fund to play an active educational role in the acquisition, production and dissemination of medical and scientific knowledge, towards the medical community, patients, and general public, under the supervision of a Scientific Committee. www.the-nash-education-program.com/en

About NASH:

“NASH”, or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is associated with long term risk of progression to cirrhosis, a state where liver function is diminished, leading to liver insufficiency, and also progression to liver cancer.


GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT’s approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT – ISIN: FR0004163111). www.genfit.com

Forward Looking Statement / Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company’s continued ability to raise capital to fund its development, as well as those discussed or identified in the Company’s public filings with the AMF, including those listed under Section 7 “Main Risks and Uncertainties” of the Company’s Half Year 2016 Business and Financial Report, which is available on GENFIT’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

GENFIT | Jean-François Mouney – Chairman & CEO | Ph. +333 2016 4000
MILESTONES – Press Relations | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com

quis ipsum vel, dictum id sit ut dolor Donec Lorem fringilla Sed